| Literature DB >> 23483618 |
Afshin Borhani Haghighi1, Nahid Ashjazadeh, Anahid Safari, Salvador Cruz-Flores.
Abstract
BACKGROUND: Cerebral venous sinus thrombosis (CVST) is a frequent cause of cerebrovascular disease in Iran.Entities:
Keywords: Causality; Clinical Manifestations; Epidemiology; Iran; Mortality; Sinus Thrombosis, Intracranial
Year: 2012 PMID: 23483618 PMCID: PMC3587871 DOI: 10.5812/ircmj.3728
Source DB: PubMed Journal: Iran Red Crescent Med J ISSN: 2074-1804 Impact factor: 0.611
Methodological and Demographic Characteristics of Patients with CVST in Iranian Series
| City | Popultaion (2006) | Etnicity | Methodology | Date of patient recruitment | Study population | Age (Mean, range) | Female/Male | Hospital stay (Mean, days) | Follow up | Duration of f/u | Functional disability | Mortality | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Mashhad | 2,868,350 | Mainly Fars | Prospective | 2005-2008 | 62 | 32.3 (18 - 62) | 51/11 | NM | NM | NM | NM | NM |
|
| Tehran | 7,705,036 | Mainly Fars | Retrospective | 2003-2008 | 41 | 37.2 (15 - 75) | 31/10 | NM | 25/41 | 3m | 13/25 | 5/41 (12.2%) |
|
| Tabriz | 1,597,319 | Mainly Turkish | Retrospective | 2003-2006 | 64 | 43.8 (16 - 80) | 55/9 | NM | NM | NM | 17/64 (26.6%) | 5/64 (7.8%) |
|
| Isfahan | 1,583,609 | Mainly Fars | Retrospective | 1997-2001 | 55 | 29.5 (17 - 71) | 42/13 | NM | NM | NM | NM | NM |
|
| Isfahan | 1,583,609 | Mainly Fars | Prospective | 2001-2004 | 122 | 35.5 ( 17 - 70) | 96/26 | NM | NM | NM | NM | NM |
|
| Shiraz | 1,227,331 | Mainly Fars | Prospective | 2000-2008 | 124 | 34.01 ± 10.25 (?-?) | 87/37 | NM | 124/124 | NM | 35.48% | 18/124 (14.51%) |
|
| Kermanshah | 784,602 | Mainly Kurdish | Prospective | 2010 | 21 | 36.00 (18 - 55) | 18/3 | NM | NM | NM | NM | NM |
|
| - | 7,705,036 | Mainly Fars | Retrospective | 1993-1999 | 39 | 42 (14 - 19) | 30/9 | NM | NM | NM | NM | NM |
|
| 528 | 410/118 = 3.47 | 28/229=12.2% |
Predisposing Factors of Patients With CVST in Iranian Series a
|
Ghnadehari ( |
Sahraian ( |
Pashapour ( |
Saadatnia ( |
Ashjazadeh ( |
Shobeiri ( |
Salimipour ( | |
|---|---|---|---|---|---|---|---|
|
| 62(51/11) | 41(31/10) | 64 (55/9) | 55(42/13) | 124(87/37) | 21(18/3) | 39(30/9) |
|
| 29(56.8%) | 22(71%) | 28(50.9%) | 27 (64% ) | 57(65.5%) | 11(61.1%) | 12(40%) |
|
| 3(5.9%) | 3(9.7%) | - | 3(7.1%) | 10(11.5%) | 1(5.5%) | - |
|
| 2(3.9%) | NM | 9(16.4%) | 4(9.5%) | 10(11.5%) | NM | 1(3.3%) |
|
| 18(29%) | NM | NM | NM | NM | NM | NM |
|
| 1(1.6%) | NM | 2(3.1%) | 6(10.9%) | 13(10.5%) | NM | NM |
|
| NM | NM | NM | 2(3.6%) | NM | NM | NM |
|
| 9(13.8%) | NM | 15(23.4%) | 9(16.4%) | 5 (4%) | 1(4.8%) | 1(2.6%) |
|
| 1(1.6%) | 3(7.3%) | 2(3.1%) | 4(7.2%) | 11(8.9%) | NM | 9(30%) |
|
| NM | 2(4.9%) | NM | 2(3.6%) | NM | NM | NM |
|
| 1(1.6%) | 3(7.3%) | NM | 2(3.6%) | NM | NM | NM |
|
| 2(3.2%) | NM | NM | NM |
12(9.7%) | NM | NM |
|
| 15(24.2%) | NM | 8(12.5%) | 11(20%) | 16(12.9%) | NM | 8(20.5%) |
aIn all series some patients had multiple contributing factors
bInflammatory Diseases: Inflammatory connect tissue diseases2011 ICD-9-CM Diagnosis Code 710 and 714 and inflammatory bowel disease
cHypercoagulable state: included in 2011 ICD-9-CM Diagnosis Code 289.81 and 289.82
dMiscelalnous includes malignancy, trauma and liver diseases
Site Involvement in Patients With CVST in Iranian Series (Any Involvement Single or Combined )
|
Ghandehari ( |
Sahrarian ( |
Pashapour ( |
Saadatnia ( |
Ashjazadeh ( |
Shobeiri ( |
Salimipour ( | |
|---|---|---|---|---|---|---|---|
|
| 62 | 41 | 64 | 55 | 124 | 21 | 39 |
|
| NM | 11(26.8%) | 50(78.1%) | 40(72%) | 80% | 15(71.4%) | 18(46.2%) |
|
| NM | 6(14.6%) | 13(20.3%) | 11(20%) | 46% | 20(95.2%) | 18(46.2%) |
|
| NM | 3(7.3%) | 6(9.4%) | NM | NM | 11(52.4%) | NM |
|
| NM | NM | NM | NM | 2(9.5%) | NM | |
|
| NM | 1(2.4%) | NM | NM | 5.2% | NM | 2(5.1%) |
|
| NM | NM | NM | 3(5.4%) | 3.2% | NM | NM |
|
| NM | NM | NM | NM | NM | 4(19%) | NM |
|
| NM | NM | NM | 1(1.8%) | NM | 3(14.3%) | NM |
Clinical Manifestations of Patients With CVST in Iranian Series
|
Ghandehari ( |
Sahraian ( |
Pashapour ( |
Saadatnia ( |
Ashjazdaeh ( |
Shobeiri ( |
Salimipour ( | |
|---|---|---|---|---|---|---|---|
|
| NM | 33 (80%) | 62 (96.9%) | 52 (94.5%) | 116 (93.54%) | 20 (95.2%) | NM |
|
| NM | 4 (9.75%) | 45 (70.3%) | 40 (72.7%) | 48 (62.3%) | NM | NM |
|
| NM | 8 (19.5%) | 2 (3.12%) | 25 (45.4%) | 31 (25%) | NM | NM |
|
| NM | 16(39%) | 41 (64%) | 25 (45.4%) | 44 (35.48%) | NM | NM |
|
| NM | 10 (20.4%) | 25 (39%) | 32 (58.1%) | 28 (36.4%) | 10 (47.62%) | NM |
|
| NM | 24 (58.5%) | 15 (23.4%) | 6 (10.9%) | NM | 10 (47.6%) | NM |
aAcute confusional state, delirium, stupor, coma, Mental disturbances
bUnilateral senory and/or motor changes
cParenchymal or subarachnoid hemorrhage